dc.contributor.author | Babu, Hari S | |
dc.contributor.author | Mason, Robert | |
dc.contributor.author | West, Nicholas P | |
dc.contributor.author | Ben, Gunawan | |
dc.contributor.author | Cox, Amanda J | |
dc.contributor.author | Nelson, Tiffanie M | |
dc.contributor.author | Zhang, Ping | |
dc.contributor.author | Cripps, Allan W | |
dc.contributor.author | Sanmugarajah, Jasotha | |
dc.date.accessioned | 2021-03-09T02:55:01Z | |
dc.date.available | 2021-03-09T02:55:01Z | |
dc.date.issued | 2020 | |
dc.identifier.issn | 0732-183X | |
dc.identifier.doi | 10.1200/JCO.2020.38.15_suppl.e15152 | |
dc.identifier.uri | http://hdl.handle.net/10072/402982 | |
dc.description.abstract | Background: The gut microbiome has been shown to modify the efficacy of cancer immunotherapy. Currently, there is little understanding of how the microbiome in advanced cancer patients responding to immunotherapy compares to healthy individuals. The aim of this study was to characterise the intestinal microbiome in patients with advanced solid organ tumours that have a durable response to programmed-death-protein-1 inhibitors (PD-1) with healthy individuals. Methods: Ten patients (mean age 69 ± 11; 60% female) with metastatic melanoma, renal cell carcinoma or non-small cell lung cancer and durable response for greater than one year to anti-PD-1 antibodies and ten healthy age and sex matched individuals (mean age 69 ± 9.2; 60% female) were recruited. Clinical data and a three-day diet diary were collected, with faecal sample analysed via shallow shotgun sequencing (CoreBiome, Minneapolis, USA). Results: Duration of response to immunotherapy was 786 ± 282 days. Responders had a significantly higher body mass index (28 ± 5.5 kg/m2 v 23.3 ± 2.65 kg/m2, p = 0.005; mean ± SD) than the healthy group. There was a significantly higher intake of total fat and fibre in the healthy group. The responder group had significantly higher diversity metrics, exhibiting a greater diversity in the number (OTUs) and the richness of species than the healthy group. At the phylum level, the microbiome in the responder group was significantly abundant in proteobacteria and had a significantly lower abundance of Bacteroidetes compared to the healthy group. At the genus level, the microbiome in the responder group was significantly enriched in Desulfovibrio, Acideminococcus, Klebsiella, Enterococcus and Faecalitalea compared to Ruminococcus, Veillonella and Roseburia in the healthy group. Species that were abundantly higher in the cancer group were associated with glycolysis, the TCA cycle, sugar metabolism and amino acid metabolism. Five Kyoto Encyclopedia of Genes and Genomes (KEGG) orthologues were significantly enriched in the responder group, mostly relating to transport systems for minerals and nitrogen fixation, but also mismatch repair proteins and cell cycle activity. Conclusions: Our findings suggest that compositional and functional differences in the faecal microbiome exist between advanced cancer patients responding to immunotherapy and healthy individuals, suggesting not only potential mechanisms of durable response but also targets for future therapy. | |
dc.description.sponsorship | Gold Coast Hospital and Health Service | |
dc.language | English | |
dc.publisher | Lippincott Williams & Wilkins | |
dc.relation.ispartofconferencename | Annual Meeting of the American Society of Clinical Oncology (ASCO) | |
dc.relation.ispartofconferencetitle | Journal of Clinical Oncology | |
dc.relation.ispartofdatefrom | 2020-05-29 | |
dc.relation.ispartofdateto | 2020-05-31 | |
dc.relation.ispartoflocation | Online | |
dc.relation.ispartofissue | 15 | |
dc.relation.ispartofvolume | 38 | |
dc.subject.fieldofresearch | Clinical sciences | |
dc.subject.fieldofresearch | Oncology and carcinogenesis | |
dc.subject.fieldofresearchcode | 3202 | |
dc.subject.fieldofresearchcode | 3211 | |
dc.subject.keywords | Science & Technology | |
dc.subject.keywords | Life Sciences & Biomedicine | |
dc.subject.keywords | Oncology | |
dc.title | Cancerbiome: Defining a healthy microbiome for therapeutic targeting | |
dc.type | Conference output | |
dc.type.description | E3 - Conferences (Extract Paper) | |
dcterms.bibliographicCitation | Babu, HS; Mason, R; West, NP; Ben, G; Cox, AJ; Nelson, TM; Zhang, P; Cripps, AW; Sanmugarajah, J, Cancerbiome: Defining a healthy microbiome for therapeutic targeting, Journal of Clinical Oncology, 2020, 38 (15) | |
dc.date.updated | 2021-03-08T03:32:28Z | |
gro.hasfulltext | No Full Text | |
gro.griffith.author | Cripps, Allan W. | |
gro.griffith.author | Cox, Amanda J. | |
gro.griffith.author | West, Nic P. | |
gro.griffith.author | Zhang, Ping | |